The Oncotype DX® Breast Cancer Assay

What is the Oncotype DX® Breast Cancer Assay?
Oncotype DX® is a test that examines a breast cancer patient's tumour tissue at a molecular level, and gives information about the patient's individual disease. By providing an individualised assessment of the magnitude of chemotherapy benefit and the likelihood of distant recurrence at 10 years, Oncotype DX® can inform adjuvant treatment decisions.

Who is Eligible for the Oncotype DX® Breast Cancer Assay?
The Oncotype DX® assay is intended to be used by women with early-stage (Stage I or II), node-negative, oestrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy and for post-menopausal women with node-positive (up to 3 nodes positive), oestrogen receptor-positive (ER+) invasive breast cancer.

What is required for the Oncotype DX® assay to be performed and how long does it take?
The Oncotype DX® assay is a 21-gene assay which is performed on formalin-fixed, paraffin-embedded tumour tissue by the developers of the assay, Genomic Health Inc. The result is available within 14 days of commencement of the test.

To order the test or for more information, please call 020 7299 4490 or email ihsenquiries@unilabs.com

For complete information on Oncotype DX® visit www.Oncotypedx.com